8-K: NEXGEL Announces Preliminary 2024 Results and Positive 2025 Outlook

NEXGEL reports strong revenue growth in 2024 and anticipates positive cash flow in 2025.

Summary

• NEXGEL expects fourth quarter 2024 revenue of approximately $3.0 million.
• Full year 2024 revenue is estimated to be approximately $8.6 million, representing over 100% year-over-year growth for the third consecutive year.
• The company anticipates generating at least $13 million in revenue for 2025.
• NEXGEL expects to achieve positive cash flow from operations during 2025.
• The company's growth is driven by contract manufacturing, consumer products, and aspirational medical device development.
• Contract manufacturing saw increased demand from existing customers and the onboarding of new global corporations.
• Consumer products expanded due to the success of the Medagel brand, acquisitions of Kenkoderm and Silly George, and a partnership with Stada.
• Silly George's annual revenue run rate increased from $2 million to over $5 million after being acquired.
• The partnership with Stada is progressing well, with the first product exceeding projections and two additional product launches expected in the second half of 2025.
• A preclinical proof of concept study using a hydrogel patch to deliver topical apremilast showed encouraging early results.

Sentiment

Score: 9

Explanation: The document conveys a very positive outlook with strong revenue growth, successful acquisitions, and a clear path to profitability. The management's confidence and the positive results of the preclinical study further boost the sentiment.

Positives

• NEXGEL experienced significant revenue growth in 2024, exceeding 100% year-over-year for the third consecutive year.
• The company is projecting strong revenue growth for 2025, with a target of at least $13 million.
• NEXGEL expects to achieve positive cash flow from operations in 2025.
• The acquisition of Silly George has been successful, with revenue increasing significantly.
• The partnership with Stada is performing well, with the first product exceeding projections.
• The company has a healthy pipeline of potential new customers for 2025.
• The preclinical study of the hydrogel patch for topical apremilast delivery showed promising early results.

Negatives

• The preliminary financial results are subject to change pending finalization and audit.
• The company's independent registered public accounting firm has not reviewed the preliminary financial information.

Risks

• The preliminary financial results are based on estimates and assumptions and are subject to change.
• The company's actual results may differ materially from the forward-looking statements due to various risks and uncertainties.
• The company's future success depends on its ability to execute its growth strategy and manage its operations effectively.

Future Outlook

NEXGEL anticipates significant growth in 2025, driven by its core business segments and new product launches, and expects to achieve positive cash flow from operations during the year.

Management Comments

• 2024 was a transformative year for NEXGEL and I have high expectations for 2025.
• We believe the future is bright with many significant opportunities.
• Our focus remains firmly on delivering long-term value for our shareholders.
• With a strong foundation and significant opportunities on the horizon, we believe that 2025 will be a landmark year.

Industry Context

The announcement reflects a positive trend in the medical and consumer healthcare sectors, with a focus on innovative products and strategic partnerships. The company's growth in contract manufacturing and consumer products aligns with the increasing demand for outsourced manufacturing and branded healthcare products.

Comparison to Industry Standards

• NEXGEL's revenue growth of over 100% year-over-year for three consecutive years is significantly higher than the average growth rate for many companies in the medical device and consumer healthcare sectors.
• Companies like Integra LifeSciences and Medline Industries, which are also involved in medical device manufacturing, typically experience more moderate growth rates.
• The company's focus on hydrogel technology and its applications in various sectors is a unique selling point compared to companies with more traditional product lines.
• The successful integration of Silly George and the partnership with Stada demonstrate effective execution of strategic initiatives, which is a key differentiator in the competitive healthcare market.

Stakeholder Impact

• Shareholders are expected to benefit from the company's strong revenue growth and positive cash flow outlook.
• Employees may experience increased job security and opportunities for advancement due to the company's growth.
• Customers will have access to new and innovative products from NEXGEL and its partners.
• Suppliers may see increased demand for their products and services due to the company's expansion.
• Creditors may have increased confidence in the company's ability to repay its debts due to its improved financial performance.

Next Steps

• Finalization of financial results for the fourth quarter and year ended December 31, 2024.
• Publication of the study on the carcinogenic plume generated by laser hair removal.
• Launch of new Medagel products, including a SilverSeal wound and burn kit and moist burn pads.
• Launch of new Kenkoderm products for an additional indication.
• Launch of new beauty under-eye patch using NEXGEL's hydrogel technology.
• Launch of two additional products from the Stada partnership.
• Continuation of the preclinical study using a hydrogel patch to deliver topical apremilast.

Key Dates

Keywords

hydrogels, medical devices, contract manufacturing, consumer products, revenue growth, cash flow, preclinical study, acquisitions, partnerships, OTC products